Cheng-pin Chen - Publications

Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 20, 2026

Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in naïve people living with HIV of Asian OrigiN (DRAGON).

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: September 28, 2025

Risk factors for mpox infection among MSM with STIs in northern Taiwan, 2022-2024.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: April 22, 2025

Concordance of Oral and Anal Human Papillomavirus in Men Who Have Sex With Men Living With Human Immunodeficiency Virus.

Journal: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

Published: October 07, 2024

IoT-Based Hand Hygiene Compliance Monitoring System and Validation of Its Effectiveness in Hospital Environments.

Journal: Global challenges (Hoboken, NJ)

Published: May 09, 2024

Oncogenic human papillomavirus and anal microbiota in men who have sex with men and are living with HIV in Northern Taiwan.

Journal: PloS one

Published: May 06, 2024

Drug monitoring was conducted for rifapentine among people with HIV receiving dolutegravir containing antiretroviral therapy and latent tuberculosis treatment.

Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

Published: April 15, 2024

A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.

Journal: Infectious diseases and therapy

Published: March 20, 2024

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.

Journal: PloS one

Published: March 18, 2024

Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.

Journal: Nature communications

Published: February 05, 2024

The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.

Journal: PLoS pathogens

Published: December 01, 2023

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222.

Journal: Vaccines

Published: September 15, 2022